Rhythm Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
222 Berkeley St Fl 12, Boston, Massachus...Phone Number
(857) 264-4280Website
www.rhythmtx.comRevenue
$239.9 MillionStock Symbol
RYTMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of people living with rare neuroendocrine diseases. The company focuses on developing and delivering precision medicines that address the underlying biological causes of complex and often underserved medical conditions. Through its research, development, and commercialization efforts, Rhythm Pharmaceuticals works to improve treatment options for patients who have historically faced limited therapeutic choices.Explore more
Rhythm Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rhythm Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Rhythm Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Rhythm Pharmaceuticals launches new products
Earning: See what the market has to say on Rhythm Pharmaceuticals recently announced quarterly report
Check out if Rhythm Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Rhythm Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Rhythm Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Rhythm Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Rhythm Pharmaceuticals
Compare insights from companies similar to Rhythm Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rhythm Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rhythm Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals financials insights
Gather financial insights about Rhythm Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$40M
2012
Series B
$33M
2017
Other Financing Round
$41M
Stock Offering
$138M
2018
Stock Offering
$174M
2019
Stock Offering
$172.5M
2022
Debt
$100M
2024
Series A
$150M
Rhythm Pharmaceuticals Tech Stack
A closer look at the technologies used by Rhythm Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Project
Rhythm Pharmaceuticals News & Media
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Could this little-known biotech be a hidden gem?Rhythm (NASDAQ: RYTM) CTO sells 5079 shares in 10b5-1 plan - Stock Titan
CTO Joseph Shulman exercised 2,024 options at $6.80 and sold 5,079 shares at $119.75 on 2026-08-13 in a 10b5-1 plan, leaving 5,945 options.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rhythm Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of people living with rare neuroendocrine diseases. The company focuses on developing and delivering precision medicines that address the underlying biological causes of complex and often underserved medical conditions. Through its rese... Read More
